Skip to main content

Roche to Introduce Six GeneChip-Based Diagnostics Within 18 Months

NEW YORK, May 7 - A Roche official said today that the Swiss pharma giant will introduce six new diagnostic products over the next 18 months based on the Affymetrix GeneChip platform it licensed in January.

 

In a widely reported news conference in Switzerland, Heino von Prondzynski, the head of Roche's diagnostics division identified what tests the company plans to introduce into the market.

 

Initially, the company will roll out the AmpliChip CYP450 microarray for lab use in the US in May. The chip, designed by Roche and manufactured by Affymetrix, will be sold as an analyte-specific reagent.

 

Then, the company will also launch Affymetrix platform diagnostic tests for human papilloma virus, cystic fibrosis, colorectal cancer, HIV, and leukemia.

 

Roche officials were not available for comment.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.